scholarly article | Q13442814 |
P2093 | author name string | Jin-Hwang Liu | |
Liang-Tsai Hsiao | |||
Po-Min Chen | |||
Tzeon-Jye Chiou | |||
Wei-Shu Wang | |||
Chueh-Chuan Yen | |||
Jen-Tsun Lin | |||
Frank S Fan | |||
Hung-Ming Chung | |||
P2860 | cites work | Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 |
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor | Q33941495 | ||
Severe adverse cutaneous reactions to drugs | Q34314152 | ||
Cutaneous reactions to STI571. | Q43723840 | ||
A NEW ERUPTIVE FEVER ASSOCIATED WITH STOMATITIS AND OPHTHALMIA | Q56066353 | ||
Induction of hyperacute graft-vs-host disease after donor leukocyte infusions | Q74623404 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | imatinib | Q177094 |
Stevens–Johnson syndrome | Q1053948 | ||
P304 | page(s) | 620-622 | |
P577 | publication date | 2002-06-01 | |
P1433 | published in | British Journal of Haematology | Q4970200 |
P1476 | title | Stevens-Johnson syndrome after treatment with STI571: a case report | |
P478 | volume | 117 |
Q38729029 | A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor |
Q44339633 | A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). |
Q37930709 | Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. |
Q45152647 | Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors |
Q38103997 | Adverse skin effects of imatinib, a tyrosine kinase inhibitor |
Q54987295 | Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies. |
Q37433981 | Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor |
Q28070095 | Cutaneous complications of molecular targeted therapy used in oncology |
Q44964913 | Cutaneous side effects with imatinib (Glivec) |
Q80178563 | Desensitization to imatinib in patients with leukemia |
Q45227567 | Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib |
Q36753920 | Erythema multiforme and related disorders |
Q46972774 | Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib |
Q42087836 | Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib |
Q33662660 | Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor. |
Q37183434 | Imatinib mesylate for the treatment of chronic myeloid leukemia |
Q38101103 | Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. |
Q36705526 | Imatinib-induced Stevens-Johnsons syndrome |
Q45023013 | Lichenoid cutaneous reaction to imatinib |
Q41869634 | Life-threatening dermatologic adverse events in oncology |
Q44665259 | Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing |
Q35748794 | Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™) |
Q50897717 | Pityriasis rubra pilaris-like reaction induced by imatinib |
Q34443523 | Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase |
Q34666762 | Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia |
Q55115766 | Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. |
Q45610652 | Stevens-Johnson Syndrome Induced by Sorafenib for Metastatic Renal Cell Carcinoma |
Q36822880 | Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). |
Q40466877 | [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy] |
Search more.